TUSC2 and non-small cell lung carcinoma: TUSC2 downregulation of MDM2 increases p53 expression and promotes Apaf-1 activation, which enhances NSCLC chemosensitivity to cisplatin treatment, resulting in greater inhibition of tumor growth and increased apoptosis [79].